CAMBRIDGE, MA--(Marketwired - May 7, 2013) - Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, today announced that it has initiated dosing in a Phase 1 multiple ascending dose (MAD) clinical trial of ...MSN Money · 5/7/2013